The purpose of the study is to assess the safety of ipilimumab and dasatinib combination therapy in patients with CML
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
IV Solution, IV, 10 mg/kg, (if dose reduction necessary at 3 mg/kg), Every three weeks for the first 10 weeks, with a booster at week 22, Up to 38 weeks depending on response
The University Of Texas, M.D. Anderson Cancer Center
Houston, Texas, United States
To evaluate the safety of ipilimumab in combination with dasatinib in CML patients with a loss of previously achieved major molecular response or a loss of previously achieved cytogenetic response to dasatinib
Time frame: At weeks 1, 4, 7, 10, 14, 18, 22, 26, 30, 34 and 38
To evaluate the frequency of molecular response, complete cytogenetic response and an overall efficacy signal response rate
Time frame: At weeks 1, 4, 7, 10, 14, 18, 22, 26, 30, 34 and 38
To explore the immunologic responses to combination therapy with ipilimumab and dasatinib
Time frame: At weeks 1, 4, 7, 10, 14, 18, 22, 26, 30, 34 and 38
To explore whether molecular responses to combination therapy with ipilimumab and dasatinib correlate with immunologic responses
Time frame: At weeks 1, 4, 7, 10, 14, 18, 22, 26, 30, 34 and 38
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.